S100A4 and neoplasm: Combination with antibody blockade of S100A4 also reduced liver fibrosis without inhibiting the anti-CD137 antibody anti-tumor response in the MC38 mouse colorectal cancer (CRC) model, suggesting that simultaneously targeting S100A4 may be viable to alleviate immunotherapy-associated liver toxicity in some contexts (65).